- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00414180
Bupropion SR for Treating Smokeless Tobacco Use
Study Overview
Detailed Description
CONTEXT: No pharmacotherapies have been shown to increase long-term (≥ 6 month) tobacco abstinence rates among smokeless tobacco (ST) users, although bupropion SR has demonstrated potential efficacy in pilot studies.
OBJECTIVE: To determine the efficacy and safety of bupropion SR for tobacco abstinence among ST users compared with placebo.
DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial conducted between August 2003 to May 2005 at two research centers with a 12-week treatment period and follow-up of smoking status to week 52.
INTERVENTION: Bupropion SR titrated to 150 mg twice daily or placebo for 12 weeks plus weekly behavioral interventions.
Main Outcome Measures: The primary endpoint was 7-day point-prevalence tobacco abstinence rate at week 12. Secondary outcomes included the prolonged and continuous tobacco abstinence rates at weeks 12, 24, and 52.
Study Type
Enrollment
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- used ST daily for at least one year
- in good general health
- willing to complete all study procedures
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
7-day point-prevalence tobacco abstinence rate at week 12
|
Secondary Outcome Measures
Outcome Measure |
---|
prolonged and continuous tobacco abstinence rates at weeks 12, 24, and 52
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lowell C. Dale, M.D., Mayo Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Dopamine Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Dopamine Uptake Inhibitors
- Bupropion
Other Study ID Numbers
- 06-007293
- R01 9088
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smokeless Tobacco
-
Masonic Cancer Center, University of MinnesotaRecruitingSmokeless TobaccoUnited States
-
University of MinnesotaWithdrawn
-
Duke UniversityCompletedSmokeless Tobacco CessationUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedSmokeless Tobacco CessationUnited States
-
Mayo ClinicCompleted
-
Duke UniversityNational Cancer Institute (NCI)Completed
-
Oregon Research InstituteNational Cancer Institute (NCI); Mayo ClinicCompletedSmokeless Tobacco CessationUnited States
-
HealthPartners InstituteMinnesota Partnership for Action Against TobaccoCompleted
-
Mayo ClinicOregon Research InstituteCompleted
-
Oregon Research InstituteCompleted
Clinical Trials on Bupropion SR
-
Orexigen Therapeutics, IncCompleted
-
National Institute on Drug Abuse (NIDA)CompletedTobacco Use Disorder | Tobacco Use CessationUnited States
-
Watching Over Mothers & Babies FoundationUniversity of ArizonaCompleted
-
National Institute on Drug Abuse (NIDA)CompletedSchizophrenia | Tobacco Use DisorderUnited States
-
James DavisAxsome Therapeutics, Inc.CompletedSmoking Cessation | Nicotine Dependence | Smoking, CigaretteUnited States
-
Orexigen Therapeutics, IncCompleted
-
Orexigen Therapeutics, IncCompletedObesity | OverweightUnited States
-
Mayo ClinicNational Cancer Institute (NCI); University of MinnesotaCompleted
-
University of Alabama at BirminghamNot yet recruiting
-
G&E Herbal Biotechnology Co., LTDCompletedActinic Keratosis | Bowen's DiseaseTaiwan